-
This simple strength test could predict how long you live
Staying strong may be one of the biggest secrets to living longer — especially for older women. A major study of more than 5,000 women found that simple signs of muscle strength, like a firm hand grip or the ability to quickly stand up from a chair, were strongly linked to lower risk of death…
-
‘Heart-on-a-chip’ project to help researchers study BMD, DMD
Duchenne Parent Project Spain is investing €247,000 (just over $290,000 USD) in a project that aims to create a new laboratory model to study how the heart is affected in people with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The “heart-on-a-chip” platform will allow researchers to grow heart cells in a three-dimensional architecture…
-
What MDA Summer Camp taught me about why we show up
This article was provided by our partner, the Muscular Dystrophy Association. It has been reviewed by Bionews for accuracy and relevance. The views and opinions expressed are those of the author and do not necessarily reflect the views of Bionews or Muscular Dystrophy News Today. I grew up being educated on how I could help my…
-
Remembering a dear friend, who taught me about leaving a legacy
My dear friend Colin Rensch had a saying: “If you think you can, then of course you can.” I met Colin because I live with limb-girdle muscular dystrophy, and he lived with Duchenne muscular dystrophy. Colin, who defined passion, purpose, and positivity, passed away last month at the age of 32. I’ve written in the…
-
Guest Voice: After diagnosis, focusing on what we can do
It started long before I had the words to explain it. At 9 years old, I noticed small things: I struggled to lift my arms the same way as my friends, I grew tired more quickly, and others were much faster than me. But at that age, it was easy to brush those things off.…
-
In Case You Missed It…
Quest Media is an innovative, adaptive lifestyle platform from MDA. With the power of this platform, we foster awareness and empowerment and have important conversations with experts, thought leaders, and members of the neuromuscular disease community about topics that matter to them and to the larger community of individuals with disabilities. With so many valuable…
-
Talking with my daughter about her journey with DMD carrier status
I have been writing here about my family since August 2021. My husband, Jason, and I share seven children: Lexi, 25; Max, 20; Chance, 19; Rowen, 17; Charlie, 15; Mary, 11; and Callie, 4. Max, Rowen, and Charlie have Duchenne muscular dystrophy (DMD). In my first column, I shared that my husband and I were…
-
When “No Options” Starts to Change: A New Chapter for Seronegative Myasthenia Gravis
For many people living with generalized myasthenia gravis (gMG), the journey is not just defined by symptoms—it’s shaped by uncertainty. Uncertainty in diagnosis. Uncertainty in treatment. And for a significant subset of the community, uncertainty in whether therapies designed for others will work for them at all. That’s why moments like this matter. The recent…
-
Entrada Therapeutics announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients amenable to skipping exon 44.
Entrada Therapeutics, who received early funding from CureDuchenne to advance their Endosomal Escape Vehicle Platform, today announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients amenable to skipping exon 44. Read press release HERE The post Entrada Therapeutics announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients…
-
Companies join forces to speed production of 1-time treatment for FSHD
Epicrispr Biotechnologies is partnering with Forge Biologics to support the development of EPI-321, Epicrispr’s one-time epigenetic treatment candidate for facioscapulohumeral muscular dystrophy (FSHD). The treatment uses epigenetics — chemical modifications that can alter gene activity without changing a gene’s DNA sequence — to turn off the abnormally-activated gene that underlies FSHD. According to the developer,…
